Immunohistochemical expression of hormone receptors, Ki-67, endoglin (CD105), claudins 3 and 4, MMP -2 and -9 in endometrial polyps and endometrial cancer type I

Background and objectives: Endometrial polyps in asymptomatic postmenopausal women are often incidentally found, yet only 1.51% of them are malignant. Their potential for malignant transformation has not been adequately addressed. The aim of this study was to investigate the proliferation within endometrial polyps as one of the indicators of their malignization potential in asymptomatic postmenopausal women. Materials and Methods: Immunohistochemical studies of Ki-67 were performed. Cases included 52 benign postmenopausal polyps, 19 endometrioid carcinoma with coexisting benign polyps, 12 polyps with foci of carcinoma and 4 cases of polyps, which later developed carcinoma. The control group included 31 atrophic endometria and 32 benign premenopausal polyps. Ki-67 was scored in either 10 or 20 “hot spot” fields, as percentage of positively stained cells. Results: The median epithelial Ki-67 score in postmenopausal benign polyps (4.7%) was significantly higher than in atrophic endometria (2.41%, p < 0.0001) and significantly lower than in premenopausal benign polyps (11.4%, p = 0.003) and endometrial cancer (8.3%, p < 0.0001). Where endometrial polyps were found in association with endometrial carcinoma, Ki-67 was significantly higher in cancer (p < 0.0001). No significant difference was found between Ki-67 scores of cancer focus and of the polyps tissue itself, respectively 2.8% and 4.55%, p = 0.37. Ki-67 expression, where polyps were resected and women later developed cancer, was not significantly different (p = 0.199). Conclusion: Polyps from asymptomatic postmenopausal women showed significantly more proliferation in both epithelial and stromal components than inactive atrophic endometria but less than premenopausal benign polyps and/or endometrial cancer. Benign postmenopausal endometrial polyps exhibit low proliferative activity, suggesting low malignant potential and may not require resection in asymptomatic women.

Download Full-text

Palliative treatment of endometrial cancer type 1 in elderly women with Anastrozole.

10.21203/rs.2.21712/v1 ◽

2020 ◽

Author(s):

Barbara Gardella ◽

Mattia Dominoni ◽

Stefano Bogliolo ◽

Chiara Cassani ◽

Giulia Vittoria Carletti ◽

...

Keyword(s):

Endometrial Cancer ◽

Palliative Treatment ◽

Elderly Women ◽

Endometrial Thickness ◽

Average Rate ◽

Female Genital Tract ◽

Common Disease ◽

Type I ◽

Cancer Type ◽

Progression Of Disease

Abstract Purpose: Type I endometrial cancer is a common disease which takes place in female genital tract. The aim of the work is to asset the feasibility and safety of anastrozole in the palliative treatment of endometrial cancer in elderly women not eligible to standard surgical treatment. Methods: eight patients with histological diagnosis of endometrial cancer were enrolled in this pilot study. Anastrozole was administered 1 mg daily per os after performing an accurate radiological mapping of the lesion. A questionnaire evaluated the quality of life of these patients. Results: the median age was 85 (range 80-88years). The endometrial cancer was confined to the uterus in all patients. No progression of disease was observed. A partial response to the therapy was reported in seven patients, while no response was reported in one patient. A decrease in the symptoms such as pain, vaginal bleeding and vaginal discomfort was reported, as well as no progression of disease. The endometrial thickness after twelve months has showed a reduction of 9.25 ± 4.77 mm. The average rate of follow-up was 18.25 months. Four women died for other reasons, none of them related to endometrial cancer. Evaluation of symptoms showed a significant reduction of appetite loss and insomnia, while a significant increase of global health status and fatigue was reported. Conclusion: our preliminary data reported that the palliative use of anastrozole may be a suitable therapy for a good control of early stages of endometrial cancer in inoperable elderly women, having a good compliance and tolerance.

Download Full-text

Characteristics of endometrial carcinoma in obese women

Medicinski pregled ◽

10.2298/mpns1010709v ◽

2010 ◽

Vol 63 (9-10) ◽

pp. 709-714 ◽

Cited By ~ 1

Author(s):

Predrag Vukomanovic ◽

Ranko Kutlesic ◽

Milan Stefanovic ◽

Mileva Milosavljevic ◽

Jasmina Popovic ◽

...

Keyword(s):

Endometrial Cancer ◽

Myometrial Invasion ◽

Figo Stage ◽

Stage I ◽

Nuclear Grade ◽

Obese Group ◽

Type I ◽

Cancer Type ◽

Obese Women ◽

Grade Ii

Introduction. In most developed countries, endometrial cancer appears as most frequent invasive neoplasm of genital tract. Obesity is one of most important risk factors. Aim of study was to establish characteristics endometrial cancer in obese women. Material and methods. The study included 50 surgically treated women with endometrial cancer. According body mass index they were divided into two groups - group A (30 obese women), group B (20 non-obese women). Results and Discussion. Non-obese women with endometrial cancer are statistically significantly older than obese. Menopausal status, parity are not statistically significant. The obese group most frequently includes endometrioid type of tumor, while non-obese group most frequently includes non-endometrioid types of endometrial cancer. Over 50% thick myometrial invasion is statistically more frequent in non-obese group than in obese group. In obese group, less than 50% thick myometrial invasion, is statistically significant in comparison to non-obese group. High-differentiated endometrial cancer(G1) is statistically significantly more present in obese women than non-obese. Low-diferentiated endometrial cancer is statistically more frequent in non-obese women than in obese. Most frequent in both groups is NG2. According to FIGO stage I, disease is statistically significantly more frequent in obese group than in non-obese. In non-obese group, total number of deseased in higher stages (II and III) is statistically significantly higher than in stage I. Conclusion. Endometrial cancer present in obese women is mostly endometroid type I, with slow myometrial invasion, with hystological grade I, nuclear grade II in FIGO stage I of disease. In non-obese women, non-endometrioid cancer - type II is more frequent, with faster myometrial invasion, hystological grade II and III, nuclear grade II, in FIGO stage II of disease.

Download Full-text

Altered Peroxisome-Proliferator Activated Receptors Expression in Human Endometrial Cancer

PPAR Research ◽

10.1155/2012/471524 ◽

2012 ◽

Vol 2012 ◽

pp. 1-5 ◽

Cited By ~ 13

Author(s):

Paweł Knapp ◽

Adrian Chabowski ◽

Agnieszka Błachnio-Zabielska ◽

Katarzyna Jarząbek ◽

Sławomir Wołczyński

Keyword(s):

Endometrial Cancer ◽

Protein Expression ◽

Hormone Receptors ◽

Protein Pattern ◽

Transcriptional Level ◽

Peroxisome Proliferator ◽

Immunohistochemical Expression ◽

Mrna Content ◽

Endometrial Cancers ◽

Peroxisome Proliferator Activated Receptors

Peroxisome proliferator-activated receptors (PPARs) belong to a family of nuclear hormone receptors acting as transcriptional factors, recently involved also in carcinogenesis. Present study was undertaken to evaluate the presence and subcellular localization of different PPAR isoforms (α,β,γ) in healthy endometrial tissue (n=10) and endometrial carcinoma (FIGO I, endometrioides type, G1,n=35). We sought to analyze PPARs mRNA content as well as protein immunohistochemical expression that was further quantified by Western Blot technique. For both PPARαand PPARβ, protein expression was significantly higher in endometrial cancers compared to normal endometrial mucosa. In opposite, PPARγprotein expression was lower in endometrial cancer cells. In each case, immunohistochemical reaction was confined to the perinuclear and/or nuclear region. At the transcriptional level, the content of mRNA of all PPAR subunits did not follow the protein pattern of changes. These results provide evidence for altered PPAR's protein expression and disregulation of posttranslational processes in endometrial cancers.

Download Full-text

Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000001015 ◽

2017 ◽

Vol 27 (6) ◽

pp. 1200-1205 ◽

Cited By ~ 2

Author(s):

Francesco Fanfani ◽

Stefano Restaino ◽

Stefania Cicogna ◽

Marco Petrillo ◽

Marcella Montico ◽

...

Keyword(s):

Endometrial Cancer ◽

High Risk ◽

Gynecologic Oncology ◽

Menopausal Status ◽

Myometrial Invasion ◽

Type I ◽

Cancer Type ◽

Type Ii ◽

Human Epididymis Protein 4 ◽

Human Epididymis

ObjectiveThe aim of the study was to evaluate the prognostic value of human epididymis protein 4 (HE4) and cancer antigen 125 markers with pathological prognostic factor to complete the preoperative clinical panel and help the treatment planning.MethodsThis prospective multicenter study was conducted in 2 gynecologic oncology centers between 2012 and 2014 (Institute for Maternal and Child Health IRCCS Burlo Garofolo in Trieste and Catholic University of the Sacred Heart in Rome, Italy). We enrolled 153 patients diagnosed with clinical early (International Federation of Gynecology and Obstetrics stages I–II) type I endometrial cancer.ResultsHuman epididymis protein 4 levels seemed to be strictly related to age (P < 0.001) and menopausal status (P < 0.002). Compared with myometrial invasion (MI), the HE4 values were significantly higher in case of invasion of greater than 50% of the thickness: MI of greater than 50%, median of 94.85 pmol/L (38.3–820.8 pmol/L), versus MI of less than 50%, median of 65.65 pmol/L (25.1–360.2 pmol/L), (P < 0.001). The HE4 levels increase significantly with increasing tumor size: diameter of larger than 2 cm, median of 86.9 pmol/L (35.8–820.8 pmol/L), versus diameter of smaller than 2 cm, median of 52.2 pmol/L (33.3–146.8 pmol/L), (P < 0.001). In our population, HE4 did not correlate with the histological grade, endometrial cancer type I versus type II (P = 0.86), the lymphovascular infiltration (P = 0.12), and the cervical invasion (P = 0.6). We established a new variable, considering 3 high-risk tumor features: MI of greater than 50% and/or histological G3 and/or type II. Human epididymis protein 4 levels significantly increase in high-risk tumors (high risk HE4, 93.6 pmol/L vs low-medium risk, 65.5 pmol/L; P < 0.001).ConclusionsA preoperative HE4 evaluation could help stratify patients with deep invasion and/or metastatic disease and is correlated with other relevant prognostic factors to be considered to tailor an adequate surgical strategy.

Download Full-text

LYMPHADENECTOMY IN ENDOMETRIAL CANCER TYPE I - STAGE I AND II: ARE THERE ADVANTAGES?

10.26226/morressier.5770e29ed462b80290b4c5bc ◽

2016 ◽

Author(s):

Elaine Candido

Keyword(s):

Endometrial Cancer ◽

Stage I ◽

Type I ◽

Cancer Type

Download Full-text

Canonical and noncanonical Wnt pathways: a comparison between endometrial cancer type I and atrophic endometrium in Brazil

Sao Paulo Medical Journal ◽

10.1590/s1516-31802011000500007 ◽

2011 ◽

Vol 129 (5) ◽

pp. 320-324 ◽

Cited By ~ 3

Author(s):

Marina de Pádua Nogueira Menezes ◽

Celina Tizuko Fujiyama Oshima ◽

Levon Badiglian Filho ◽

Thiago Simão Gomes ◽

Luis Fernando Mesias Barrezueta ◽

...

Keyword(s):

Endometrial Cancer ◽

Endometrial Adenocarcinoma ◽

Sao Paulo ◽

Tissue Type ◽

Type I ◽

Cancer Type ◽

Beta Catenin ◽

São Paulo ◽

Group A ◽

Group B

CONTEXT AND OBJECTIVE: The Wnt pathway is involved in tumorigenesis of several tissues. For this reason, we proposed to evaluate Wnt gene expression in endometrial cancer type I. DESIGN AND SETTING: Cross-sectional study on materials gathered from the tissue bank of the Department of Pathology, Universidade Federal de São Paulo. METHODS: Endometrial specimens were obtained from surgeries performed between 1995 and 2005 at São Paulo Hospital, Universidade Federal de São Paulo. The material was divided into two groups according to tissue type: Group A, atrophic endometrium (n = 15); and Group B, endometrial adenocarcinoma (n = 45). We compared the immunohistochemical expression of Wnt1, Frizzled-1 (FZD1), Wnt5a, Frizzled-5 (FZD5) and beta-catenin between endometrial cancer type I and atrophic endometrium. RESULTS: Regarding Wnt1, FZD1 and Wnt5a expression, no significant association was observed between the groups. A significant association was observed between the groups in relation to FZD5 expression (P = 0.001). The proportion of FZD5-positive samples was significantly higher in group A (80.0%) than in group B (31.1%). Regarding the survival curve for FZD5 in group B, we did not find any significant association between atrophic endometrium and endometrial adenocarcinoma. We also did not find any significant association regarding beta-catenin expression (P = 1.000). CONCLUSION: FZD5 is downregulated in endometrial adenocarcinoma, in comparison with atrophic endometrium

Download Full-text

Simultaneous carcinoma of the endometrium and ovary vs. endometrial carcinoma with ovarian metastases: A clinical and immunohistochemical determination

International Journal of Gynecological Cancer ◽

10.1136/ijgc-00009577-200301000-00006 ◽

2003 ◽

Vol 13 (1) ◽

pp. 32-37

Author(s):

L. Habler ◽

R. Halperin ◽

S. Zehavi ◽

E. Hadas ◽

I. Bukovsky ◽

...

Keyword(s):

Endometrial Cancer ◽

Endometrial Carcinoma ◽

Familial Cancer ◽

Immunohistochemical Analysis ◽

Ovarian Tumors ◽

Immunohistochemical Expression ◽

Metastatic Tumors ◽

Ki 67 ◽

Ovarian Metastases ◽

Her 2

The aim of this study was to perform a clinical and immunohistochemical comparison between simultaneous independent tumors involving endometrium and ovary and metastatic endometrial tumors, and to try to find clinical and /or immunohistochemical parameters differentiating between these two entities. Sixteen cases of simultaneous independent primaries of endometrium and ovary, presenting the same histologic type, were compared with 12 cases of primary endometrial cancer, demonstrating ovarian metastases. The comparison related to patients' characteristics and immunohistochemical expression of estrogen and progesterone receptors (ER,PR), bcl-2, HER-2 /neu, p53, and cell proliferation marker Ki-67 in endometrial and ovarian tumors.The only clinical parameter differentiating significantly between the groups was the prevalence of familial cancer, being more frequent in the group of metastatic tumors (P = 0.03). Immunohistochemical analysis demonstrated the same immunostaining in endometrium and ovary for all immunohistochemical parameters in cases of metastatic endometrial cancer. Conversely, 62.5% of cases with simultaneous tumors of endometrium and ovary could be differentiated from metastatic tumors by distinct immunohistochemical expression of ER and PR in endometrial and ovarian tumors (P = 0.0006), and 31.3% of cases could be differentiated by distinct immunostaining for bcl-2 (P = 0.03). Immunohistochemical parameters HER–2 /neu, p53 and Ki-67 were not appropriate for the distinction between the two study groups. We conclude that the application of immunohistochemical analysis may play an important role in the differentiation between cases of simultaneous independent carcinomas of endometrium and ovary vs. cases of endometrial carcinoma with ovarian metastases.

Download Full-text

Uterine Commensal Peptostreptococcus Species Contribute to IDO1 Induction in Type I Endometrial Cancer Through the Production of Indoleacrylic Acid

SSRN Electronic Journal ◽

10.2139/ssrn.3659983 ◽

2020 ◽

Author(s):

Qiong Wang ◽

Yaqiong Liu ◽

Weiwei Chen ◽

Sha Chen ◽

Yulian Xu ◽

...

Keyword(s):

Endometrial Cancer ◽

Type I

Download Full-text

AGE FEATURES OF MOLECULAR-BIOLOGICAL SUBTYPES OF BREAST CANCER

Journal of Ural Medical Academic Science ◽

10.22138/2500-0918-2020-17-2-187-192 ◽

2020 ◽

Vol 17 (2) ◽

pp. 187-192

Author(s):

E.A. Novikova ◽

◽

O.V. Kostromina ◽

D.V. Mikhailov ◽

S.L. Leontiev ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptors ◽

Age Groups ◽

Luminal A ◽

Ki 67 ◽

Luminal B ◽

Age Related ◽

Age Features ◽

Immunohistochemical Studies ◽

Triple Negative Subtype

Aim. The aim of the study was to determine the presence of peculiarities of the age structure in patients with various surrogate molecular biological subtypes of breast cancer. Materials and research methods. This work analyzes the age-related characteristics of the occurrence of molecular biological subtypes in 499 patients with invasive breast cancer. All cases were divided into 5 molecular biological subtypes based on immunohistochemical studies of hormone receptors, Her2, Ki-67. The average age of the patients was 53.4±0.39 years, the predominant group was patients from 50 to 60 years (37.2% of the total). Research results. In patients under 40 years old, the triple negative subtype prevailed (44.8%). Luminal A subtype prevailed in the groups 51-60 years old (more than 41.4%) and over 60 years old (39.7%). Luminal B (Her2-) subtype was equally found in all age groups.

Download Full-text